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Abstract: In the past decade, Galleria mellonella (wax moth) larvae have become widely used as a
non-mammalian infection model. However, the full potential of this infection model has yet to be
realised, limited by the variable quality of larvae used and the lack of standardised procedures. Here,
we review larvae suitable for research, protocols for dosing larvae, and methods for scoring illness in
larvae infected with fungal pathogens. The development of standardised protocols for carrying out
our experimental work will allow high throughput screens to be developed, changing the way in
which we evaluate panels of mutants and strains. It will also enable the in vivo screening of potential
antimicrobials at an earlier stage in the research and development cycle.
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1. Introduction
The economy, ease of maintenance, and ethical acceptability has led to the widespread adoption
of Galleria mellonella (wax moth) larvae, as a non-mammalian infection model. The larvae can be
incubated at 37 ◦C, allowing the expression of temperature-regulated virulence genes. Moreover,
a defined infection site and the ability to challenge larvae with exact doses of fungi allow the 50%
lethal dose (LD50) to be calculated. This allows the virulence of mutants, or the efficacy of antifungal
compounds, to be compared and provides a major advantage over many other non-mammalian
infection models (Table 1). The innate immune system of G. mellonella shares many similarities with the
innate system of mammals [1]. Central to insect immunity are specialized phagocytic cells (hemocytes).
Like mammalian neutrophils, they show lectin-mediated phagocytosis of microorganisms and kill
via a respiratory burst mediated by NADPH oxidase [1]. Hemocytes display Toll-like receptors
and binding activates antimicrobial peptide production via an NFκB-like signalling pathway [1].
The similarities between neutrophils and hemocytes allow the complex interplay between G. mellonella
and the pathogen to be captured in a way that is not possible in cell culture infection systems. It is
likely a combination of these features which has led to the widespread adoption of G. mellonella
larvae as a model for infections caused by a wide range of fungi [2] including Aspergillus [3,4],
Candida [5–14], and Cryptococcus species [15–17], although notably, the larvae are reported to be
resistant to Pneumoncystis murina infection [18]. For some fungal pathogens, G. mellonella larvae are
now becoming the infection model of choice, with over 115 publications to date using this model with
Candida albicans.
However, we believe that the full potential of the G. mellonella infection model has yet to be
realised, held back by the variable quality of larvae used and the lack of standardised procedures for
J. Fungi 2018, 4, 108; doi:10.3390/jof4030108 www.mdpi.com/journal/jof
J. Fungi 2018, 4, 108 2 of 11
dosing larvae and recording morbidity and mortality. The aim of this review is to address the extent to
which these problems have been resolved, and to identify future work needed to provide a robust,
reliable, and consistent infection model.
Table 1. Comparison of alternative infection models.
Model Whole AnimalModel
Use at
37 ◦C
Precise
Dosing
Immune
System
Cost of Maintenance
by User
Regulated Use
in the UK
Monolayer cell cultures no yes yes no medium no
3D cell cultures no yes yes no high no
Caenorhabditis elegans
(nematode) yes no no yes low no
Panagrellus redivivus
(nematode) yes yes no yes low no
Zebra fish
(and embryos) yes no yes yes high
yes (fish and
older embryos)
Drosophila melanogaster
(fruit fly) yes yes no yes low no
G. mellonella yes yes yes yes low no
Manduca sexta
(tobacco hornworm) yes yes yes yes low
regulated as a
crop pest.
2. Reported Variability of Fungal Infection Models
As would be expected in an animal model of infection, variability is clearly apparent in the
outcome data reported. The lack of standardised procedures for conducting these studies is thought
to be a key factor contributing to the level of variability demonstrated, and this variability can
prevent the direct comparison of published studies. The methodologies employed in these studies are
broadly similar, but can display key differences in the preparation of inocula, injection volume, source
and handling of larvae, and experimental conditions such as temperature. For example, published
studies utilising the model to assess the virulence of Candida albicans mutants have reported using
inoculum levels ranging almost one hundred fold (6 × 104 to 5 × 106 cells/larva). Furthermore,
even when relatively similar procedures appear to have been employed, substantial variation can still
be seen in the results published. For example, two recently published studies in C. albicans [19,20],
utilising comparable wild type strains at the same inoculum level, reported mortality at five days to
be either 20% or 60%. Another study measuring the virulence of 51 C. albicans transcription factor
mutants in G. mellonella larvae reported only a 45% correlation between the results from replicate
experiments, which they attributed to variability of the larvae [21]. Issues such as these may potentially
be overcome through the standardization of assay protocols, plus the introduction of well-characterised
G. mellonella lines.
3. Standardization of G. mellonella Larvae
Tsai et al. [22] have previously identified the lack of standardised G. mellonella larvae as a
significant barrier to the wider adoption of this model for bacterial pathogens. For many years,
G. mellonella larvae have been commercially available as food for captive reptiles and birds or as fishing
bait, and larvae bred for these purposes have been widely used in research. These larvae are not
age- or weight-defined, and have been bred, reared, and maintained under differing conditions. Age,
feeding status, and physical handling of larvae have all been reported to have a significant impact
on the susceptibility of the larvae to infection [23,24]. Furthermore, the larvae may contain antibiotic
and hormone residues [25]. This can result in inconsistent responses of larvae to infection, possibly
reflecting altered metabolism in the larvae [26]. To address these problems, standardised G. mellonella
larvae (TruLarv™) are now available (www.BioSystemsTechnology.com). These larvae are purpose
bred for research without antibiotics or hormones added to feedstuff. They are age and weight defined
and the cuticle of the larvae is decontaminated, reducing the problem of infections in control animals
injected with PBS. The use of these larvae as an infection model, in place of pet-food grade larvae, has
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been seen to have a major impact on the consistency and reproducibility of experiments with bacterial
pathogens [27,28], and may also reduce the level of variation seen with fungal pathogens.
4. Standardization of Challenge and Dosing
The most common method of infection is by injection of the larvae. This allows precise doses of a
fungal pathogen to be given and consequently it is possible to calculate the LD50. There is also some
interest in challenging larvae by the oral route. However, the larvae that are commercially available
are fifth or sixth instar stage, and they feed little during this final phase before pupation. Therefore,
oral dosing can only be achieved by using earlier instar stage larvae, or by oral gavage. These different
dosing routes are reviewed below.
4.1. Subcutaneous Microinjection
Methods vary between laboratories, but commonly larvae are injected with 10 µL innocula (up to
40 µL innocula have also been used [5,21]) by sub cutaneous micro-injection into a defined site (often
a proleg), using either a Hamilton or fine insulin syringe [29,30]. The exact type of needle used
for injection needs to be considered in the context of the volume delivered. For example, insulin
syringes have 10 µL increments, meaning that there may be error in delivering exactly 10 µL. The most
precise delivery of 10 µL necessitates the use of a 10 µL Hamilton syringe. In some laboratories,
larvae are immobilized between the operator’s fingers and the needle inserted into the insect’s proleg,
lifting the needle away from the operator with the insect attached before pushing the plunger on the
syringe [31]. To reduce the risk of needle stick injury, a range of safety procedures have been developed
by laboratories, including immobilising larvae over a pipette tip fixed to filter paper, the use of a
stab-proof glove during injections [32], and a restraint device comprised of sponge and a bulldog clip
termed the “Galleria grabber” [30].
Infected larvae may be incubated at temperatures ranging from 15 ◦C to 37 ◦C, as required.
The ability to incubate larvae at 37 ◦C facilitates studies involving temperature-regulated virulence
genes. PBS and uninfected controls are included in studies to ensure that larval death is not a result of
trauma due to the injection. Groups of ten larvae are generally used in an experiment, with two or
three experimental replicates providing large data sets for statistical analyses [29,33–35].
4.2. Feeding Larvae
To mimic the physiological route of natural exposure to microbes, G. mellonella have sometimes been
fed microbes in their diet. Variations of this method have been reported, for example, Freitak et al. [36]
fed third instar G. mellonella larvae a standard wax moth diet drenched with LB broth for control
groups, or mixtures of microbial cultures in test groups [36]. Similarly, Chertkova et al. [37] used the
oral route of infection. Following oral infection of G. mellonella larvae with combinations of microbes,
the concentration of dopamine was measured at different time points in the haemolymph [37]. In this
study, the oral inoculation of fourth instar larvae was performed after mixing microorganisms with
artificial medium. Control groups were fed on artificial medium mixed with saline.
4.3. Oral Gavage
Forced feeding of G. mellonella larvae has been reported in microbial infection studies [38,39].
To administer a suspension of microbes, oral gavage is required, in which a blunted microinjector
syringe is gently inserted into the mouth piece of final instar larvae and 20 µL inoculum is delivered [40].
5. Standardised Scoring
Early studies using G. mellonella as an infection model scored larval death as the endpoint, typically
measured as the ability of larvae to move or respond to physical stimuli with a pipette tip. The use of a
well-defined endpoint allows calculation of the LD50. A modification of this approach is to calculate
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the “virulence index” based on the time to death of 50% of the cohort, but normalised to the time to
death of the wild type and expressed as a log value [14,41,42]. By calculating the virulence index, it is
possible to compare data between laboratories more simply. However, the monitoring of larval death
in this way at frequent intervals can be very time consuming, and therefore it is usual to score the
larvae at 12 or 24 h intervals. Whilst this can reduce the workload, it can also result in fine differences
in the time to death being missed.
Other ways of measuring infection include recording the progressive melanisation of larvae
(Figure 1), the direct enumeration of pathogens within body tissues, and histology on infected larvae.
These methods all have different benefits and drawbacks. In our experience, the degree of melanisation
is dependent on the infecting pathogen. Some pathogens cause profound and uniform melanisation,
whilst others cause more subtle colour changes which can be difficult to interpret. The enumeration of
pathogen load in tissues, or histology, both require the culling and processing of larvae which can be
time consuming. Pathogen load at given time-points may also be calculated by homogenising the larvae
and enumerating fungi after plating onto suitable media. The fungal load in larval compartments such
as the cadaver, hemolymph, and hemocoel, may be established by draining hemolymph from infected
larvae and using centrifugation to separate hemocytes from the hemolymph. Finally, the inability to
form a silk cocoon by pupating larvae (Figure 1) indicates poor health.
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Figure 1. Changes in the appearance of G. mellonella larvae after infection (B) compared to healthy
final instar stage larvae (A). Reproduced from [22] with the permission of the authors. Progressive
melanisation of l e is shown from right (none) to left (complete).
Against this background, a pathological scoring system (Table 2) has been proposed by Loh et al. [43].
This system allows subtle differences in larval health to be assessed based on their appearance (Figure 1).
It also facilitates greater reproducibility, and the comparison of data, between different laboratories.
However, this scoring system still relies on time consuming checks. In the future, automated real-time
imaging of larvae, possibly using the criteria outlined in Table 1, would ope up opportunities for
high throughput screens to be devised.
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Table 2. The G. mellonella health index scoring system [43].
Category Description Score
activity no movement 0
minimal movement on stimulation 1
move when stimulated 2
move without stimulation 3
cocoon formation no cocoon 0
partial cocoon 0.5
full cocoon 1
melanisation black larvae 0
black spots on brown larvae 1
≥3 spots on beige larvae 2
<3 spots on beige larvae 3
no melanisation 4
survival dead 0
alive 2
6. High Throughput Screens
The low cost and ease with which G. mellonella larvae can be injected have prompted suggestions
that this infection model could be used for high-throughput screening, either to identify virulence
genes or to screen antifungal drugs. An important issue is how reliably these screens in G. mellonella
larvae predict behaviour in mammals. There are some pivotal experiments which shed light on this
question. In a study with C. neoformans, 46 of 66 mutants found to be attenuated in G. mellonella
larvae (70%) had previously been shown to be attenuated in mice [44]. In contrast, the same study
found that only 29% of mutants found to be attenuated in C. elegans were attenuated in mice [44].
The authors concluded that the increased discriminating power of G. mellonella likely reflects the greater
similarity of the immune system to the mammalian immune system. In another study, the virulence of
18 C. albicans mutants was compared in mice and in G. mellonella larvae, and there was found to be a
50% correlation between the two lists of attenuated mutants [21]. However, mutants with strongly
attenuated phenotypes in mice were much better predicted in G. mellonella larvae. This finding suggests
that G. mellonella larvae are well suited to identifying gene products which play the most important
roles in infection, and which are in any case likely to be the most attractive targets for interventions and
exploitation. These findings add significant weight to the argument that high throughput screening
using G. mellonella larvae provides meaningful results.
6.1. High Throughput Screening of Mutant Libraries
It is feasible to test large panels (up to 264) of fungal mutants individually in larvae [14,44,45].
However, to improve the statistical power of these studies, and because of the variability of responses
of pet-shop larvae, groups of up to 50 larvae have been reported to be required for each mutant
tested [14]. Clearly, the need to work with large cohorts of larvae would limit the number of mutants
that can be tested simultaneously, and therefore the potential to carry out high throughput screens.
Another approach would involve the simultaneous screening of mixtures of mutants or strains.
By marking the different genotypes, for example, each with a unique DNA tag, it is possible to track
the individual mutants within the population. Therefore, by tracking the abundance of DNA tags,
genotypes which are more or less competitive (i.e., more or less virulent) in vivo are revealed. This
approach has previously been widely used with bacterial and fungal pathogens in mammalian models
of disease [46–51]. A major advantage of this high-throughput screen is the ability to test large groups
(thousands or tens of thousands) of mutants or strains simultaneously in a single animal. Therefore,
relatively small numbers of larvae can be used. But there is also a major disadvantage in that the
virulence phenotype may not be revealed when pools of mutants are tested [21]. In some cases, this is
because “cheater” mutants are able to survive and grow because other members of the population
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provide the necessary factors masking the virulence defect [21]. Notwithstanding this concern, this
approach has been used to simultaneously compare the virulence of a panel of 4110 mutants of
Saccharomyces cerevisiae in G. mellonella larvae [52]. This study found that genes involved in cell wall
integrity, mitochondrial function, and tyrosine metabolism play key roles in disease.
6.2. Screening for Antifungal Agents
Previous studies have found a good correlation between the efficacy of antifungal drugs in
mammalian infection models and in G. mellonella models of disease [2]. G. mellonella larvae might enable
high-throughput drug screening in two ways. One relies on an initial in vitro screen of compounds,
followed by the testing of selected compound(s) in larvae. This could allow the testing of compounds
in larvae at an earlier stage and on a larger scale than would be possible if mammals were used. This
approach has already been used to identify novel antimicrobials [53–70].
Alternatively, compounds could be tested individually in G. mellonella larvae at the earliest
possible stage. This approach has the advantage that the most promising leads are identified, but
the disadvantage that compounds with low bioavailability or low stability in vivo may be missed.
Many early stage compounds are poorly soluble in water, and testing may require the drug to be
dissolved in a solvent such as dimethyl sulfoxide (DMSO), ethanol, or methanol. In our hands, even
small (10 µL) volumes of these solvents are lethal to G. mellonella larvae unless diluted to 20% (v/v)
DMSO or 30% (v/v) ethanol [71]. Other limitations of this approach are the number of larvae that can
be dosed with compound and pathogen, the feasibility of keeping large cohorts of larvae, and the
feasibility of recording morbidity and mortality or large groups of larvae.
There are reports of the parallel screening of relatively small panels (<30) of antimicrobial compounds
for activity towards microorganisms [72,73]. However, there has been little reported progress in
developing G. mellonella larvae for screening larger panels of compounds in high-throughput screens.
In part, this may reflect the variability of responses seen between pet-food grade larvae. For example,
in one study, test groups of 30 larvae were used per test compound [73]. The availability of larvae
that behave consistently might now allow screening with smaller groups of larvae and open new
opportunities for high throughput screening.
7. Discussion
The larvae of the wax moth G. mellonella are undoubtedly becoming a popular model for
studying microbial virulence and treatment options, as evidenced through both the expanding
range of pathogens tested in the system and the growing number of reports utilising the model.
The model is increasingly being accepted as an alternative to mammalian infection models, which
are subject to greater ethical and logistical constraints. In addition, it displays key advantages over
other invertebrate models, such as its ability to be maintained at human body temperature, and the
ease of handling and delivery of a precise infective dose. Furthermore, these attributes allow large
numbers of larvae to be infected, therefore facilitating its use for the large-scale screening of virulence
factors or antimicrobial activities of candidate drugs. However, this model does suffer from some
limitations and disadvantages, mainly surrounding the lack of standardised protocols and a standard
well-characterised G. mellonella strain (Table 3).
There are a range of factors to consider when standardising the handling of wax moth
larvae, including their age and size, availability of food [24], the physical stress associated with
transportation [23], and incubation temperature and storage time [24]. Larvae from breeders supplying
pet shops have also been seen to carry residual levels of antibiotics and hormones [25], and these have
been suggested to have an impact on the variability seen in the model with bacterial pathogens and
may also lead to an altered outcome with fungal pathogens. All of these factors can impact the response
of larvae to infection, and therefore impact the level of variability seen with the model. Until recently,
there has also been the lack of a standardised G. mellonella strain, with most reports utilising larvae
from commercial pet-shop breeders, or occasionally through research groups maintaining their own
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colony. Therefore, in addition to differences in rearing and maintenance, strain differences may also
impact the variability seen in the assay. Recently, however, the first commercial supplier of “research
grade” larvae (TruLarv™) has been established, and early reports suggest that their use has lowered
the level of variability seen with bacterial pathogens [28]. Finally, the wax moth model still lacks an
annotated genome and the genetic tractability available in other insect models. However, the first
report of a G. mellonella genome has recently been released [74], and this will hopefully now lead to its
annotation to support the initial transcriptomics analysis of immune system genes [75]. This resource
could then facilitate the development of molecular tools in G. mellonella in order to further our ability
to use this increasingly popular model to dissect the host-pathogen interaction.
Table 3. Approaches to standardizing experiments using G. mellonella larvae.
Model Limitations Consequences Solution
Differences in age, weight and
health status of larvae
Lack of reproducibility between
experiments Use age and weight defined larvae
Antibiotic and hormone residues
Lack of reproducibility between
experiments. May distort the results
of tests of antimicrobial efficacy
Use larvae bred without the use of
antibiotics or hormones
Genetic diversity of G. mellonella Lack of reproducibilitybetween experiments Use inbred breeding colony
Larvae have a surface flora of
pathogenic microorganisms
Deaths in controls when injected
with PBS Surface decontaminate larvae
Larvae normally available
do not feed
Difficult to dose orally with
pathogens or chemicals
Use early instar stage larvae or
Oral gavage
Scoring or morbidity or mortality
can be subjective End points are not well defined Use Heath Index Scoring System
Dosing involves injection of small
volumes
Dose of pathogen given is not
precisely determined Use Hamilton syringes
High throughput screening is
limited by operator ability to inject
large numbers of larvae
Screens are size limited
Reduce cohort size using
standardised larvae or Develop
automated screens
Author Contributions: Conceptualization, O.L.C. and R.W.T.; Writing—Original Draft Preparation, O.L.C., R.W.T.
and S.B.; Writing—Review & Editing, O.L.C., R.W.T. and S.B.
Funding: This research received no external funding.
Conflicts of Interest: Olivia L. Champion and Richard W. Titball have an interest in BioSystems Technology
Limited. Steven Bates declares no conflict of interest.
References
1. Browne, N.; Heelan, M.; Kavanagh, K. An analysis of the structural and functional similarities of insect
hemocytes and mammalian phagocytes. Virulence 2013, 4, 597–603. [CrossRef] [PubMed]
2. Binder, U.; Maurer, E.; Lass-Florl, C. Galleria mellonella: An invertebrate model to study pathogenicity in
correctly defined fungal species. Fungal Biol. 2016, 120, 288–295. [CrossRef] [PubMed]
3. Jackson, J.C.; Higgins, L.A.; Lin, X. Conidiation color mutants of Aspergillus fumigatus are highly pathogenic
to the heterologous insect host Galleria mellonella. PLoS ONE 2009, 4, e4224. [CrossRef] [PubMed]
4. Geissel, B.; Penka, M.; Neubauer, M.; Wagener, J. The ER-mitochondria encounter structure contributes to
hyphal growth, mitochondrial morphology and virulence of the pathogenic mold Aspergillus fumigatus. Int. J.
Med. Microbiol. 2017, 307, 37–43. [CrossRef] [PubMed]
5. Cotter, G.; Doyle, S.; Kavanagh, K. Development of an insect model for the in vivo pathogenicity testing of
yeasts. FEMS Immunol. Med. Microbiol. 2000, 27, 163–169. [CrossRef] [PubMed]
J. Fungi 2018, 4, 108 8 of 11
6. Brennan, M.; Thomas, D.Y.; Whiteway, M.; Kavanagh, K. Correlation between virulence of Candida albicans
mutants in mice and Galleria mellonella larvae. FEMS Immunol. Med. Microbiol. 2002, 34, 153–157. [CrossRef]
[PubMed]
7. Borman, A.M.; Szekely, A.; Johnson, E.M. Comparative pathogenicity of United Kingdom isolates of the
emerging pathogen Candida auris and other key pathogenic Candida species. mSphere 2016, 1, e00189-16.
[CrossRef] [PubMed]
8. Junqueira, J.C.; Fuchs, B.B.; Muhammed, M.; Coleman, J.J.; Suleiman, J.M.; Vilela, S.F.; Costa, A.C.;
Rasteiro, V.M.; Jorge, A.O.; Mylonakis, E. Oral Candida albicans isolates from HIV-positive individuals
have similar in vitro biofilm-forming ability and pathogenicity as invasive Candida isolates. BMC Microbiol.
2011, 11, 247. [CrossRef] [PubMed]
9. Borghi, E.; Andreoni, S.; Cirasola, D.; Ricucci, V.; Sciota, R.; Morace, G. Antifungal resistance does not
necessarily affect Candida glabrata fitness. J. Chemother. 2014, 26, 32–36. [CrossRef] [PubMed]
10. Gago, S.; Garcia-Rodas, R.; Cuesta, I.; Mellado, E.; Alastruey-Izquierdo, A. Candida parapsilosis,
Candida orthopsilosis, and Candida metapsilosis virulence in the non-conventional host Galleria mellonella.
Virulence 2014, 5, 278–285. [CrossRef] [PubMed]
11. Souza, A.C.; Fuchs, B.B.; Pinhati, H.M.; Siqueira, R.A.; Hagen, F.; Meis, J.F.; Mylonakis, E. Candida parapsilosis
resistance to fluconazole: Molecular mechanisms and in vivo impact in infected Galleria mellonella Larvae.
Antimicrob. Agents Chemother. 2015, 59, 6581–6587. [CrossRef] [PubMed]
12. Mesa-Arango, A.C.; Forastiero, A.; Bernal-Martinez, L.; Cuenca-Estrella, M.; Mellado, E.; Zaragoza, O.
The non-mammalian host Galleria mellonella can be used to study the virulence of the fungal pathogen
Candida tropicalis and the efficacy of antifungal drugs during infection by this pathogenic yeast. Med. Mycol.
2013, 51, 461–472. [CrossRef] [PubMed]
13. Moralez, A.T.; Perini, H.F.; Furlaneto-Maia, L.; Almeida, R.S.; Panagio, L.A.; Furlaneto, M.C. Phenotypic
switching of Candida tropicalis is associated with cell damage in epithelial cells and virulence in
Galleria mellonella model. Virulence 2016, 7, 379–386. [CrossRef] [PubMed]
14. Ames, L.; Duxbury, S.; Pawlowska, B.; Ho, H.L.; Haynes, K.; Bates, S. Galleria mellonella as a host model to
study Candida glabrata virulence and antifungal efficacy. Virulence 2017, 8, 1909–1917. [CrossRef] [PubMed]
15. Gago, S.; Serrano, C.; Alastruey-Izquierdo, A. Molecular identification, antifungal resistance and virulence
of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain. Mycoses 2017, 60, 40–50.
[CrossRef] [PubMed]
16. Firacative, C.; Duan, S.; Meyer, W. Galleria mellonella model identifies highly virulent strains among all major
molecular types of Cryptococcus gattii. PLoS ONE 2014, 9, e105076. [CrossRef] [PubMed]
17. Mylonakis, E.; Moreno, R.; El Khoury, J.B.; Idnurm, A.; Heitman, J.; Calderwood, S.B.; Ausubel, F.M.;
Diener, A. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect. Immun.
2005, 73, 3842–3850. [CrossRef] [PubMed]
18. Fuchs, B.B.; Bishop, L.R.; Kovacs, J.A.; Mylonakis, E. Galleria mellonella are resistant to Pneumocystis murina
infection. Mycopathologia 2011, 171, 273–277. [CrossRef] [PubMed]
19. Bohovych, I.; Kastora, S.; Christianson, S.; Topil, D.; Kim, H.; Fangman, T.; Zhou, Y.J.; Barrientos, A.; Lee, J.;
Brown, A.J.; et al. Oma1 Links mitochondrial protein quality control and TOR signaling to modulate
physiological plasticity and cellular stress responses. Mol. Cell. Biol. 2016, 36, 2300–2312. [CrossRef] [PubMed]
20. Patterson, M.J.; McKenzie, C.G.; Smith, D.A.; da Silva Dantas, A.; Sherston, S.; Veal, E.A.; Morgan, B.A.;
MacCallum, D.M.; Erwig, L.P.; Quinn, J. Ybp1 and Gpx3 signaling in Candida albicans govern hydrogen
peroxide-induced oxidation of the Cap1 transcription factor and macrophage escape. Antioxid. Redox Signal.
2013, 19, 2244–2260. [CrossRef] [PubMed]
21. Amorim-Vaz, S.; Delarze, E.; Ischer, F.; Sanglard, D.; Coste, A.T. Examining the virulence of Candida albicans
transcription factor mutants using Galleria mellonella and mouse infection models. Front. Microbiol. 2015,
6, 367. [CrossRef] [PubMed]
22. Tsai, C.J.; Loh, J.M.; Proft, T. Galleria mellonella infection models for the study of bacterial diseases and for
antimicrobial drug testing. Virulence 2016, 7, 214–229. [CrossRef] [PubMed]
23. Mowlds, P.; Barron, A.; Kavanagh, K. Physical stress primes the immune response of Galleria mellonella larvae
to infection by Candida albicans. Microbes Infect. 2008, 10, 628–634. [CrossRef] [PubMed]
24. Banville, N.; Browne, N.; Kavanagh, K. Effect of nutrient deprivation on the susceptibility of Galleria mellonella
larvae to infection. Virulence 2012, 3, 497–503. [CrossRef] [PubMed]
J. Fungi 2018, 4, 108 9 of 11
25. Buyukguzel, E.; Kalender, Y. Penicillin-induced oxidative stress: Effects on antioxidative response of midgut
tissues in instars of Galleria mellonella. J. Econ. Entomol. 2007, 100, 1533–1541. [CrossRef] [PubMed]
26. Browne, N.; Surlis, C.; Maher, A.; Gallagher, C.; Carolan, J.C.; Clynes, M.; Kavanagh, K. Prolonged
pre-incubation increases the susceptibility of Galleria mellonella larvae to bacterial and fungal infection.
Virulence 2015, 6, 458–465. [CrossRef] [PubMed]
27. Wagley, S.; Borne, R.; Harrison, J.; Baker-Austin, C.; Ottaviani, D.; Leoni, F.; Vuddhakul, V.; Titball, R.W.
Galleria mellonella as an infection model to investigate virulence of Vibrio parahaemolyticus. Virulence 2018, 9,
197–207. [CrossRef] [PubMed]
28. Wagley, S.; Champion, O.L.; Titball, R.W. Case Study: Identification of Virulence Genes. Available online:
https://biosystemstechnology.com/applications (accessed on 12 July 2018).
29. Champion, O.L.; Karlyshev, A.V.; Senior, N.J.; Woodward, M.; La Ragione, R.; Howard, S.L.; Wren, B.W.;
Titball, R.W. Insect infection model for Campylobacter jejuni reveals that O-methyl phosphoramidate has
insecticidal activity. J. Infect. Dis. 2010, 201, 776–782. [PubMed]
30. Dalton, J.P.; Uy, B.; Swift, S.; Wiles, S. A novel restraint device for injection of Galleria mellonella larvae
that minimizes the risk of accidental operator needle stick injury. Front. Cell. Infect. Microbiol. 2017, 7, 99.
[CrossRef] [PubMed]
31. Fuchs, B.B.; O'Brien, E.; Khoury, J.B.; Mylonakis, E. Methods for using Galleria mellonella as a model host to
study fungal pathogenesis. Virulence 2010, 1, 475–482. [CrossRef] [PubMed]
32. Harding, C.R.; Schroeder, G.N.; Collins, J.W.; Frankel, G. Use of Galleria mellonella as a model organism to
study Legionella pneumophila infection. J. Vis. Exp. 2013. [CrossRef] [PubMed]
33. Champion, O.L.; Cooper, I.A.; James, S.L.; Ford, D.; Karlyshev, A.; Wren, B.W.; Duffield, M.; Oyston, P.C.;
Titball, R.W. Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology
2009, 155, 1516–1522. [CrossRef] [PubMed]
34. Mukherjee, K.; Altincicek, B.; Hain, T.; Domann, E.; Vilcinskas, A.; Chakraborty, T. Galleria mellonella as a
model system for studying Listeria pathogenesis. Appl. Environ. Microbiol. 2010, 76, 310–317. [CrossRef]
[PubMed]
35. Seed, K.D.; Dennis, J.J. Development of Galleria mellonella as an alternative infection model for the Burkholderia
cepacia complex. Infect. Immun. 2008, 76, 1267–1275. [CrossRef] [PubMed]
36. Freitak, D.; Schmidtberg, H.; Dickel, F.; Lochnit, G.; Vogel, H.; Vilcinskas, A. The maternal transfer of bacteria
can mediate trans-generational immune priming in insects. Virulence 2014, 5, 547–554. [CrossRef] [PubMed]
37. Chertkova, E.A.; Grizanova, E.V.; Dubovskiy, I.M. Bacterial and fungal infections induce bursts of
dopamine in the haemolymph of the Colorado potato beetle Leptinotarsa decemlineata and greater wax
moth Galleria mellonella. J. Invertebr. Pathol. 2018, 153, 203–206. [CrossRef] [PubMed]
38. Fedhila, S.; Buisson, C.; Dussurget, O.; Serror, P.; Glomski, I.J.; Liehl, P.; Lereclus, D.; Nielsen-LeRoux, C.
Comparative analysis of the virulence of invertebrate and mammalian pathogenic bacteria in the oral insect
infection model Galleria mellonella. J. Invertebr. Pathol. 2010, 103, 24–29. [CrossRef] [PubMed]
39. Mukherjee, K.; Raju, R.; Fischer, R.; Vilcinskas, A. Galleria mellonella as a model host to study gut microbe
homeostasis and brain infection by the human pathogen Listeria monocytogenes. Adv. Biochem. Eng. Biotechnol.
2013, 135, 27–39. [PubMed]
40. Maguire, R.; Kunc, M.; Hyrsl, P.; Kavanagh, K. Caffeine administration alters the behaviour and development
of Galleria mellonella larvae. Neurotoxicol. Teratol. 2017, 64, 37–44. [CrossRef] [PubMed]
41. Brunke, S.; Quintin, J.; Kasper, L.; Jacobsen, I.D.; Richter, M.E.; Hiller, E.; Schwarzmuller, T.; d‘Enfert, C.;
Kuchler, K.; Rupp, S.; et al. Of mice, flies–and men? Comparing fungal infection models for large-scale
screening efforts. Dis. Model. Mech. 2015, 8, 473–486. [CrossRef] [PubMed]
42. Glittenberg, M.T.; Silas, S.; MacCallum, D.M.; Gow, N.A.; Ligoxygakis, P. Wild-type Drosophila melanogaster
as an alternative model system for investigating the pathogenicity of Candida albicans. Dis. Model. Mech.
2011, 4, 504–514. [CrossRef] [PubMed]
43. Loh, J.M.; Adenwalla, N.; Wiles, S.; Proft, T. Galleria mellonella larvae as an infection model for group
A streptococcus. Virulence 2013, 4, 419–428. [CrossRef] [PubMed]
44. Desalermos, A.; Tan, X.; Rajamuthiah, R.; Arvanitis, M.; Wang, Y.; Li, D.; Kourkoumpetis, T.K.;
Fuchs, B.B.; Mylonakis, E. A multi-host approach for the systematic analysis of virulence factors in
Cryptococcus neoformans. J. Infect. Dis. 2015, 211, 298–305. [CrossRef] [PubMed]
J. Fungi 2018, 4, 108 10 of 11
45. Lee, K.T.; So, Y.S.; Yang, D.H.; Jung, K.W.; Choi, J.; Lee, D.G.; Kwon, H.; Jang, J.; Wang, L.L.; Cha, S.; et al.
Systematic functional analysis of kinases in the fungal pathogen Cryptococcus neoformans. Nat. Commun.
2016, 7, 12766. [CrossRef] [PubMed]
46. Van Opijnen, T.; Camilli, A. Transposon insertion sequencing: A new tool for systems-level analysis of
microorganisms. Nat. Rev. Microbiol. 2013, 11, 435–442. [CrossRef] [PubMed]
47. Barquist, L.; Boinett, C.J.; Cain, A.K. Approaches to querying bacterial genomes with transposon-insertion
sequencing. RNA Biol. 2013, 10, 1161–1169. [CrossRef] [PubMed]
48. McAdam, P.R.; Richardson, E.J.; Fitzgerald, J.R. High-throughput sequencing for the study of bacterial
pathogen biology. Curr. Opin. Microbiol. 2014, 19, 106–113. [CrossRef] [PubMed]
49. Noble, S.M.; French, S.; Kohn, L.A.; Chen, V.; Johnson, A.D. Systematic screens of a Candida albicans
homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat. Genet. 2010, 42,
590–598. [CrossRef] [PubMed]
50. Liu, O.W.; Chun, C.D.; Chow, E.D.; Chen, C.; Madhani, H.D.; Noble, S.M. Systematic genetic analysis
of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 2008, 135, 174–188. [CrossRef]
[PubMed]
51. Sasse, A.; Hamer, S.N.; Amich, J.; Binder, J.; Krappmann, S. Mutant characterization and in vivo conditional
repression identify aromatic amino acid biosynthesis to be essential for Aspergillus fumigatus virulence.
Virulence 2016, 7, 56–62. [CrossRef] [PubMed]
52. Phadke, S.S.; Maclean, C.J.; Zhao, S.Y.; Mueller, E.A.; Michelotti, L.A.; Norman, K.L.; Kumar, A.; James, T.Y.
Genome-wide screen for Saccharomyces cerevisiae genes contributing to opportunistic pathogenicity in an
invertebrate model host. G3 2018, 8, 63–78. [CrossRef] [PubMed]
53. Seed, K.D.; Dennis, J.J. Experimental bacteriophage therapy increases survival of Galleria mellonella larvae
infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob. Agents Chemother.
2009, 53, 2205–2208. [CrossRef] [PubMed]
54. Deacon, J.; Abdelghany, S.M.; Quinn, D.J.; Schmid, D.; Megaw, J.; Donnelly, R.F.; Jones, D.S.;
Kissenpfennig, A.; Elborn, J.S.; Gilmore, B.F.; et al. Antimicrobial efficacy of tobramycin polymeric
nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: Formulation, characterisation and
functionalisation with dornase alfa (DNase). J. Control. Release 2015, 198, 55–61. [CrossRef] [PubMed]
55. Kamal, F.; Dennis, J.J. Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): Antibiotics stimulate
lytic phage activity. Appl. Environ. Microbiol. 2015, 81, 1132–1138. [CrossRef] [PubMed]
56. Ross-Gillespie, A.; Weigert, M.; Brown, S.P.; Kummerli, R. Gallium-mediated siderophore quenching as
an evolutionarily robust antibacterial treatment. Evol. Med. Public Health 2014, 2014, 18–29. [CrossRef]
[PubMed]
57. Antunes, L.C.; Imperi, F.; Minandri, F.; Visca, P. In vitro and in vivo antimicrobial activities of gallium nitrate
against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2012, 56, 5961–5970.
[CrossRef] [PubMed]
58. Coughlan, A.; Scanlon, K.; Mahon, B.P.; Towler, M.R. Zinc and silver glass polyalkenoate cements:
An evaluation of their antibacterial nature. Biomed. Mater. Eng. 2010, 20, 99–106. [PubMed]
59. Browne, N.; Hackenberg, F.; Streciwilk, W.; Tacke, M.; Kavanagh, K. Assessment of in vivo antimicrobial
activity of the carbene silver(I) acetate derivative SBC3 using Galleria mellonella larvae. Biometals 2014, 27,
745–752. [CrossRef] [PubMed]
60. Rowan, R.; Moran, C.; McCann, M.; Kavanagh, K. Use of Galleria mellonella larvae to evaluate the in vivo
anti-fungal activity of [Ag2(mal)(phen)3]. Biometals 2009, 22, 461–467. [CrossRef] [PubMed]
61. Gibreel, T.M.; Upton, M. Synthetic epidermicin NI01 can protect Galleria mellonella larvae from infection with
Staphylococcus aureus. J. Antimicrob. Chemother. 2013, 68, 2269–2273. [CrossRef] [PubMed]
62. Dean, S.N.; Bishop, B.M.; van Hoek, M.L. Susceptibility of Pseudomonas aeruginosa biofilm to α-helical
peptides: D-enantiomer of LL-37. Front. Microbiol. 2011, 2, 128. [CrossRef] [PubMed]
63. Chibebe Junior, J.; Fuchs, B.B.; Sabino, C.P.; Junqueira, J.C.; Jorge, A.O.; Ribeiro, M.S.; Gilmore, M.S.;
Rice, L.B.; Tegos, G.P.; Hamblin, M.R.; et al. Photodynamic and antibiotic therapy impair the pathogenesis of
Enterococcus faecium in a whole animal insect model. PLoS ONE 2013, 8, e55926. [CrossRef] [PubMed]
64. Latz, S.; Kruttgen, A.; Hafner, H.; Buhl, E.M.; Ritter, K.; Horz, H.P. Differential effect of newly
isolated phages belonging to PB1-Like, phiKZ-Like and LUZ24-Like Viruses against Multi-Drug Resistant
Pseudomonas aeruginosa under varying growth conditions. Viruses 2017, 9, 315. [CrossRef] [PubMed]
J. Fungi 2018, 4, 108 11 of 11
65. Koch, G.; Nadal-Jimenez, P.; Reis, C.R.; Muntendam, R.; Bokhove, M.; Melillo, E.; Dijkstra, B.W.; Cool, R.H.;
Quax, W.J. Reducing virulence of the human pathogen Burkholderia by altering the substrate specificity of
the quorum-quenching acylase PvdQ. Proc. Natl. Acad. Sci. USA 2014, 111, 1568–1573. [CrossRef] [PubMed]
66. Bastidas, R.J.; Shertz, C.A.; Lee, S.C.; Heitman, J.; Cardenas, M.E. Rapamycin exerts antifungal activity
in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. Eukaryot. Cell 2012,
11, 270–281. [CrossRef] [PubMed]
67. Blatzer, M.; Blum, G.; Jukic, E.; Posch, W.; Gruber, P.; Nagl, M.; Binder, U.; Maurer, E.; Sarg, B.; Lindner, H.;
et al. Blocking Hsp70 enhances the efficiency of Amphotericin B treatment in resistant Aspergillus terreus
strains. Antimicrob. Agents Chemother. 2015. [CrossRef] [PubMed]
68. Favre-Godal, Q.; Dorsaz, S.; Queiroz, E.F.; Conan, C.; Marcourt, L.; Wardojo, B.P.; Voinesco, F.; Buchwalder, A.;
Gindro, K.; Sanglard, D.; et al. Comprehensive approach for the detection of antifungal compounds using a
susceptible strain of Candida albicans and confirmation of in vivo activity with the Galleria mellonella model.
Phytochemistry 2014, 105, 68–78. [CrossRef] [PubMed]
69. Cowen, L.E.; Singh, S.D.; Kohler, J.R.; Collins, C.; Zaas, A.K.; Schell, W.A.; Aziz, H.; Mylonakis, E.; Perfect, J.R.;
Whitesell, L.; et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for
fungal infectious disease. Proc. Natl. Acad. Sci. USA 2009, 106, 2818–2823. [CrossRef] [PubMed]
70. Fuchs, B.B.; Li, Y.; Li, D.; Johnston, T.; Hendricks, G.; Li, G.; Rajamuthiah, R.; Mylonakis, E. Micafungin elicits
an immunomodulatory effect in Galleria mellonella and mice. Mycopathologia 2016, 181, 17–25. [CrossRef]
[PubMed]
71. Allegra, E.; Titball, R.W.; Carter, J.; Champion, O.L. Galleria mellonella larvae allow the discrimination of toxic
and non-toxic chemicals. Chemosphere 2018, 198, 469–472. [CrossRef] [PubMed]
72. Thomas, R.J.; Hamblin, K.A.; Armstrong, S.J.; Muller, C.M.; Bokori-Brown, M.; Goldman, S.; Atkins, H.S.;
Titball, R.W. Galleria mellonella as a model system to test the pharmacokinetics and efficacy of antibiotics
against Burkholderia pseudomallei. Int. J. Antimicrob. Agents 2013, 41, 330–336. [CrossRef] [PubMed]
73. Adamson, D.H.; Krikstopaityte, V.; Coote, P.J. Enhanced efficacy of putative efflux pump inhibitor/antibiotic
combination treatments versus MDR strains of Pseudomonas aeruginosa in a Galleria mellonella in vivo
infection model. J. Antimicrob. Chemother. 2015. [CrossRef] [PubMed]
74. Lange, A.; Beier, S.; Huson, D.H.; Parusel, R.; Iglauer, F.; Frick, J.S. Genome sequence of Galleria mellonella
(Greater Wax Moth). Genome Announc. 2018, 6, e01220-17. [CrossRef] [PubMed]
75. Vogel, H.; Altincicek, B.; Glockner, G.; Vilcinskas, A. A comprehensive transcriptome and immune-gene
repertoire of the lepidopteran model host Galleria mellonella. BMC Genom. 2011, 12, 308. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
